The association of metabolic syndrome score trajectory patterns with risk of all cancer types

Deng, Li; Liu, Tong; Liu, Chen‐An; Zhang, Qi; Song, Meng‐Meng; Lin, Shi‐Qi; Wang, Yi‐Ming; Zhang, Qing‐Song; Shi, Han‐Ping

doi:10.1002/cncr.35235

Cited by 5 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancers [ 21 , 25 ], CVDs [ 17 , 26 ], and obesity-related medical conditions [ 19 , 20 ] have been recognized as important complications as MS evolves. However, compared with CVDs, there is a lack of evidence regarding the economic burden of cancers and obesity-related medical conditions in MS populations.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal economic burden of incident complications among metabolic syndrome populations

Chong,

Chang,

Yang

et al. 2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background This study quantifies the longitudinal economic burden for a wide spectrum of incident complications, metabolic syndrome (MS)-related risk factors, and comorbidities in patients with MS. Methods This retrospective study utilized linked data from the 2013 National Health Interview Survey and the 2012–2021 National Health Insurance Research Database to identify MS individuals and their characteristics. The incidence rate of each complication was calculated as the number of complication events in the study period divided by the total person-years during follow-up. The healthcare costs of complications were analyzed using a generalized estimating equation model to determine the cost impact of complications after adjustment for patients’ characteristics. Sensitivity analyses on variables with high missing rates (i.e., cause of death, body mass index) were performed. Results Among 837 identified MS individuals over 8.28 (± 1.35) years of follow-up, the most frequent complications were microvascular diseases (incidence rate for nephropathy/retinopathy/neuropathy: 6.49/2.64/2.08 events per 100 person-years), followed by cardiovascular diseases (2.47), peripheral vascular diseases (2.01), and cancers (1.53). Death was the costliest event (event-year cost per person: USD 16,429) and cancers were the most expensive complications (USD 9,127−11,083 for non-MS- and MS-related cancers). Developing non-MS/MS-related cancers, cardiovascular diseases, and obesity-related medical conditions increased annual costs by 273% (95% CI: 181−397%)/175% (105−269%), 159% (118−207%), and 140% (84−214%), respectively. Microvascular diseases had the lowest cost impact on annual costs (i.e., 27% [17−39%]/27% [11−46%]/24% [11−37%] increases for nephropathy/neuropathy/retinopathy, respectively). Having existing comorbidities increased annual costs by 20% (osteoarthritis) to 108% (depression). Having morbid obesity (i.e., body mass index ≥ 35 kg/m2) increased annual costs by 58% (30−91%). Conclusions The economic burden from costly incident complications (i.e., cardiovascular diseases, peripheral vascular diseases, cancers), MS-related risk factors (i.e., morbid obesity), and comorbidities (i.e., depression) highlight the urgent need for early intervention to prevent MS and its progression. The comprehensive cost estimates reported in this study can facilitate the parameterization of economic analyses to identify cost-effective interventions for these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Longitudinal economic burden of incident complications among metabolic syndrome populations

Chong,

Chang,

Yang

et al. 2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

Liver Allograft Cirrhosis, Retransplant, and Mortality Secondary to Recurrent Disease After Transplant for MASH: A Systematic Review and Meta-analysis

Jatana,

Krys,

Verhoeff

et al. 2024

Transplantation

View full text Add to dashboard Cite

Background. Recurrent disease after liver transplant is well recognized for many diseases. Metabolic dysfunction–associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are leading indications for liver transplant, and there is scarce knowledge about recurrence-related end outcomes such as retransplant and mortality. This project aims to assess the proportion of patients transplanted for MASH who develop recurrent disease and adverse clinical outcomes. Methods. A systematic review and pooled proportions meta-analysis was performed by searching the following databases: MEDLINE, Embase, Scopus, Web of Science Core Collection, and Cochrane Library. Inclusion criteria were studies discussing adult patients with liver transplants secondary to MASH or presumed MASH with recurrent disease-related outcomes. Outcomes were assessed in time frames from <6 mo to ≥5 y. Results. Of 5859 records, 40 were included (16 157 patients). Recurrent MASLD and MASH (28 studies each) occurred in frequencies of 35%–49% and 11%–24%, respectively. Fibrosis occurred in 4%–25% (13 studies). Recurrent disease-related cirrhosis (13 studies), graft failure (8 studies), and retransplant (9 studies) occurred in 0%–2%, 3%–9%, and 0%–1%, respectively. Recurrent disease-related hepatocellular carcinoma (1 study) and mortality (17 studies) both had a prevalence of 0%. Studies were of moderate or high quality using the Methodological Index for Non-Randomized Studies tool. Conclusions. Recurrent MASLD and MASH after liver transplant occur frequently, but adverse clinical outcomes due to disease recurrence are infrequent, maybe due to insufficient data on long-term follow-up. Long-term outcomes after transplantation for MASLD appear favorable; however, identifying those more likely to have progressive recurrent disease leading to adverse clinical outcomes may allow for pre- and posttransplant interventions to improve outcomes further.

show abstract

Serum urea concentration and risk of 16 site-specific cancers, overall cancer, and cancer mortality in individuals with metabolic syndrome: a cohort study

Wu,

Wei,

et al. 2024

BMC Med

View full text Add to dashboard Cite

The association of metabolic syndrome score trajectory patterns with risk of all cancer types

Cited by 5 publications

References 33 publications

Longitudinal economic burden of incident complications among metabolic syndrome populations

Longitudinal economic burden of incident complications among metabolic syndrome populations

Liver Allograft Cirrhosis, Retransplant, and Mortality Secondary to Recurrent Disease After Transplant for MASH: A Systematic Review and Meta-analysis

Serum urea concentration and risk of 16 site-specific cancers, overall cancer, and cancer mortality in individuals with metabolic syndrome: a cohort study

Contact Info

Product

Resources

About